Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Acta Cytologica

The Journal of Clinical Cytology and Cytopathology

Guidelines for Authors
www.karger.com/acy_guidelines

Introduction
Submission
Conditions
Ethics
Conflict of Interest
Sections
Plagiarism Policy
Arrangement
Color Illustrations
References
Digital Object Identifier (DOI)
Supplementary Material
Self-Archiving/Green Open Access, Author's ChoiceTM,
   Funding Organizations (NIH etc.)

Video Files
Copy Editing
Proofs
Reprints



Introduction

'Acta Cytologica' is a bimonthly published journal that aims to cover all aspects within the area of both clinical cytology and cytopathology. It furthers the understanding of cytopathologic processes and facilitates the translation of current research into clinical practice. As the official journal of the International Academy of Cytology and affiliated to over 50 cytology societies around the world, 'Acta Cytologica' evaluates new and existing diagnostic applications of scientific advances as well as their clinical correlation.

The journal features Original Papers (Fine Needle Aspiration, Gynecologic Cytopathology, Nongynecologic Cytopathology, Techniques, Molecular Techniques), Novel Insights from Clinical Practice (formerly Case Reports), Letters to the Editor and Reviews.

Criteria for acceptance are quality, originality, and clarity. 'Acta Cytologica' will not consider papers that are either preliminary or purely descriptive. Reports on clinical cases are accepted only if they provide novel insight into unresolved problems of cytology and cytopathology. All articles are subject to editorial review.



Submission

Only original papers written in English are considered. Manuscripts (the preferred word-processing package is MSWord®) should be submitted online:

Online Manuscript Submission

Should you have any problems with your submission, please contact the editorial office:

    acy@karger.com

    Kari J. Syrjänen, MD
    S. Karger AG
    Editorial Office 'Acta Cytologica'
    P.O. Box
    CH-4009 Basel (Switzerland)
    Tel.  +41 61 306 1437
    Fax. +41 61 306 1434



Conditions

All manuscripts must be accompanied by a covering letter signed on behalf of all authors verifying that all the authors were active participants. Assurance should be given that the manuscript is original and not under simultaneous consideration for publication in another journal. Please provide complete financial disclosure information; download Financial Disclosure Form here.

Presentation of manuscripts should conform with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see N Engl J Med 1997;336:309-315).

All articles will undergo an in-depth peer-review process.

Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of 'Acta Cytologica' and may not be reproduced by any means, in whole or in part, without the written consent of the publisher.

For legal reasons, we must receive your 'Submission Statement' with your original (hand-written) signature. Please download, print, sign and either fax or scan it to make it legally binding.

It is the authors' responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications. Signed permission forms from the copyright holders and original authors for all previously published tables or figures must be provided.



Ethics

Published research must comply with the guidelines for human studies and animal welfare regulations. Authors should state that subjects have given their informed consent and that the study protocol has been approved by the institute's committee on human research and thus meets the standards of the Declaration of Helsinki in its revised version of 1975 and its amendments of 1983, 1989, and 1996 [JAMA 1997;277:925-926]. Information suitable to reveal the subject's identity is to be avoided. Further, authors should also state that animal experiments conform to institutional standards. Copies of these guidelines and policy statements must be available for review by the editors if necessary.



Conflict of Interest

All forms of funding and support, including that from companies, as well as any potential competing financial interests should be acknowledged in the cover letter to the editors when applicable. The statement has to be listed at the end of the article.



Sections

Original Paper (Fine Needle Aspiration, Gynecologic Cytopathology, Nongynecologic Cytopathology, Techniques, Molecular Techniques): Submitted manuscripts should be fully documented reports of original research. They must describe significant and original observations.

Review: Potential authors are asked to contact the Editor-in-Chief before submitting a paper in order to avoid clashes with other pending reviews.

Letter to the Editor: Letters to the Editor concerning articles published in 'Acta Cytologica' may be submitted for publication. They should not be more than one printed page in length. If accepted, the authors of the articles concerned will be given the opportunity to reply.

Novel Insights from Clinical Practice (formerly Case Reports): The publication space available for case reports is very limited. The journal only considers case reports with significant new insights or with an extremely unusual and memorable course. Highlighted boxes containing one or two bullet points on ' Established facts' (what is already known) and 'Novel insights' (what new information has been gained) are required and should be placed on the first page of the report. These should be selected so as to reinforce the novelty of the clinical observation.

Example:

Established Facts

  ·    Already known fact 1 ...      

  ·    Already known fact 2 ...

  ·     ...

Novel Insights

  ·    New information 1 ...          

  ·    New information 2 ...

  ·     ...



Plagiarism Policy

Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation.
If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).



Arrangement

General: Manuscripts should be written in English and be as concise as possible. The length of the text should be limited to approximately 3,000 words, pages numbered consecutively, starting with the title page, and continuing in the following order: abstract and key words, body of text, references, figure legends and tables. Use generic names of drugs when possible. For any trade name cited, capitalize the first letter, and include the manufacturer's name and location (city, state/province, country). Express weights and measures in metric values. Acknowledge any presentation at a national or international medical society and any substantive financial support.

Title page: The first page of each paper should indicate the title, the authors' names, the institute(s) where the work was conducted, and a short title for use as running head.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as an e-mail address.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

Abstract: Each paper needs an abstract limited to 200 words structured as follows: Objective, Study design, Results and Conclusions. For Novel Insights from Clinical Practice the headings should be: Background, Case and Conclusion. Address the study's power to detect a difference if the research identified important variables that lacked a statistically significant difference.

Footnotes: Footnotes should be avoided. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

Materials and Methods: Acknowledge that the original research was approved by the local institutional review board. Clearly state the method of any randomization, blinding and selection of specific statistical tests. Explain dropouts/exclusions and confounding variables.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate pages. Tables require a heading and figures a legend, also prepared on a separate page. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180x223 mm) or provide crop marks. Each illustration must be labelled with its number and the first author's name. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling (final size), line art drawings one of 800–1,200 dpi. Do not modify a low-resolution image by increasing the dpi. Figure files should not be embedded in a document file but submitted separately. All illustrations must include the original magnification and the stain employed, and clearly identify critical areas of radiographs, photomicrographs, etc. Provide sufficient information for a table to stand alone. Avoid tables in which the data could be included in the text in a few sentences.



Color Illustrations

For all manuscripts accepted, authors will be charged CHF 500.00 for each color page published in the print version of the journal. Several color illustration may be placed onto one color page. When the illustration appears in black and white in the printed version, the authors will not be charged a fee. In the online version all figures submitted in color will appear in color at no charge to the author. Referring to colors in the text and figure legends should be avoided. We recommend using symbols, instead of color, for charts and graphs.



References

In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as 'unpublished data' and not be included in the reference list. The list of references should include only those publications which are cited in the text. In general, avoid listing unpublished data or manuscripts, personal communications, web sites and non-peer-reviewed publications. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors.

Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Authors using EndNote® may choose the format setting for Intervirology for the correct format of References.

Examples

(a) Papers published in periodicals: Vilhelmsson M, Johansson C, Jacobsson-Ekman G, Crameri R, Zargari A, Scheynius A: The malassezia sympodialis allergen Mala s 11 induces human dendritic cell maturation, in contrast to its human homologue manganese superoxide dismutase. Int Arch Allergy Immunol 2007;143:155–162.

(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.

(c) Monographs: Matthews DE, Farewell VT: Using and Understanding Medical Statistics, ed 4, revised. Basel, Karger, 2007.

(d) Edited books: Park BK, Sanderson JP, Naisbitt DJ: Drugs as haptens, antigens, and immunogens; in Pichler WJ (ed): Drug Hypersensitivity. Basel, Karger, 2007, pp 55–65.



Digital Object Identifier (DOI)

S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org



Supplementary Material

Multimedia files and other supplementary files, directly relevant but not essential to the conclusions of a paper, enhance the online version of a publication and increase its visibility on the web. These files will undergo editorial review. The Editors reserve the right to limit the scope and length of the supplementary material. Multimedia and supplementary material should meet production quality standards for publication without the need for any modification or editing. Files should not exceed 10 MB in size. Figures and tables need to have titles and legends, and all files should be supplied separately and labeled clearly. All supplementary material should be referred to in the main text. A DOI number will be assigned to supplementary material and it will be hosted online at https://karger.figshare.com under a CC BY license.



Self-Archiving/Green Open Access

Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution’s internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:

  • Be used for noncommercial purposes only
  • Be linked to the final version on www.karger.com
  • Include the following statement:

‘This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/?doi=[insert DOI number].’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author’s behalf [see Funding Organizations (NIH etc.)].

For self-archiving Author's ChoiceTM (Gold Open Access) articles, see Author's ChoiceTM.


Author's ChoiceTM

Karger’s Author's ChoiceTM service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.
The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Reposted Open Access articles must:

  • Follow the terms of the relevant Creative Commons license
  • Be linked to the final version on www.karger.com
  • Include the following statement:

‘The final, published version of this article is available at http://www.karger.com/?doi=[insert DOI number].’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.


Funding Organizations (NIH etc.)

The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author's ChoiceTM, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCUK) for submission to PMC.
Authors should include information on their grant in the Acknowledgements section of their papers.



Video Files

Video files for the 'Acta Cytologica' enhance the online versions. The printed journal remains the archival version. Since it does not contain video files, the latter can only be supplements which improve the reader's understanding of the paper. In the printed version they should be replaced by a 'typical' figure.



Copy Editing

All manuscripts accepted for publication by Karger are subject to copy editing. Changes introduced by the copy editor and/or questions will be marked in the manuscript so please be sure to check the proofs against the manuscript. The copy edited manuscript will be returned along with the proofs.



Proofs

Unless indicated otherwise, proofs are sent to the first-named author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer's errors, are charged to the author. No page proofs are supplied.



Reprints

An order form and a price list are sent with the proofs. Orders submitted after the release of an article in print are subject to considerably higher prices.